The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-07-05), Lonza Group's 9-Day RSI is 85.92.
The industry rank for Lonza Group's 9-Day RSI or its related term are showing as below:
STU:LO3's 9-Day RSI is ranked worse than 98.17% of 219
companies
in the Medical Diagnostics & Research industry
Industry Median: 53.92
vs STU:LO3: 85.92
Lonza Group (STU:LO3) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Lonza Group 9-Day RSI Related Terms
STU:LO3 vs TMO, DHR, IDXX: 9-Day RSI Comparison
For the Diagnostics & Research subindustry, Lonza Group's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lonza Group 9-Day RSI vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Lonza Group's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Lonza Group's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lonza Group (STU:LO3) has a 9-Day RSI of 85.92 as of Jul. 05, 2026. According to the industry distribution chart, Lonza Group ranks #215 out of 219 companies in the Medical Diagnostics & Research industry, placing it in the top 98.2%.
Is Lonza Group's 9-Day RSI too high?
Lonza Group's current 9-Day RSI is 85.92. The Medical Diagnostics & Research industry median 9-Day RSI is 53.92. Lonza Group's value of 85.92 is 59.3% above this industry median. Based on the distribution chart, Lonza Group ranks #215 out of 219 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Lonza Group has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Lonza Group's 9-Day RSI compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Lonza Group ranks #215 out of 219 companies for 9-Day RSI. This places Lonza Group in the lower half of its industry. The industry median 9-Day RSI is 53.92. Lonza Group's value of 85.92 is 59.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Medical Diagnostics & Research company?
The median 9-Day RSI among Medical Diagnostics & Research companies is 53.92, based on 219 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lonza Group's current 9-Day RSI of 85.92 is 59.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median 9-Day RSI is 53.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lonza Group's current 9-Day RSI is 85.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lonza Group stock overvalued right now?
Based on GuruFocus' analysis, Lonza Group (STU:LO3) is currently considered Fairly Valued. The stock's GF Value™ is €645.09, compared to a current price of €623.60 — trading 3.3% below its estimated fair value. The current 9-Day RSI is 85.92 and 59.3% above the Medical Diagnostics & Research industry median of 53.92. Lonza Group's overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Lonza Group (STU:LO3), the current 9-Day RSI is 85.92 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lonza Group (STU:LO3) Overvalued in 2026?
Based on GuruFocus' analysis, Lonza Group stock appears to be undervalued.
The current stock price of €623.60 is trading 3.3% below its estimated GF Value™ of €645.09.
GuruFocus considers Lonza Group to be Fairly Valued.
Key valuation signals for STU:LO3:
9-Day RSI: 85.92
GF Value™: €645.09 vs. price of €623.60 (3.3% below fair value)
Industry Position: 59.3% above the Medical Diagnostics & Research median (#215 of 219)
No single metric tells the full story. See the STU:LO3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lonza Group is a contract development and manufacturing organization. It operates under four segments: small molecules, biologics, cell and gene, and capsules and health ingredients. Lonza derives its revenue primarily from long-term supply agreements with pharmaceutical customers. The company provides development and manufacturing services throughout the entire lifecycle of a product, from drug research to commercial supply. The majority of Lonza's customers are pharmaceutical and biotechnology companies, academic institutions, and government research organizations.
83GF Score
Get the complete analysis for STU:LO3
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:LO3 has been successfully added to your 